Holen Sie sich die Stockscreener-App
10.61
3.46%
-0.375
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Wellington Management Group LLP Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Readystate Asset Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of New York Mellon Corp Invests $2.78 Million in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Grants Inducement Stock Options to Newly Appointed CFO Jason V. O’Byrne - quiverquant.com
Olema Pharmaceuticals (NASDAQ: OLMA) grants CFO 650K options expiring in 2036 - Stock Titan
Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire
Olema Oncology will join three investor conferences in New York this September - Stock Titan
BlackRock Inc. Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals Inc. (OLMA) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Olema Pharmaceuticals Inc. (OLMA) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Jupiter Topco LLC Takes $88.80 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Bank of America Corp DE Raises Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Olema Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:OLMA) - MarketBeat
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Olema Oncology appoints Jason O’Byrne as CFO - The Pharma Letter
OLMA Maintained by JP Morgan -- Price Target Lowered to $46.00 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals, Inc. Announces Appointment of Jason O?Byrne to Chief Financial Officer, Effective August 11, 2026 - marketscreener.com
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $46 - moomoo.com
Olema Pharmaceuticals Names Jason O'Byrne as New CFO with Comprehensive Compensation Package - Kalkine Media
Form 8K Olema Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
HC Wainwright Brokers Decrease Earnings Estimates for OLMA - MarketBeat
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer - The Manila Times
Olema Oncology’s New CFO Brings More Than Two Decades in Biotech - Stock Titan
Olema Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Harmon Cyrus - Moomoo
Olema stock falls 12.9% as Q2 loss widens to $63.2M on R&D spend - scanx.trade
OLMA Maintains Rating by Citigroup -- Price Target Lowered to $5 - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup - MarketBeat
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 - TradingView
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings - MarketBeat
Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39.9, Implies 234% Upside - TradingView
OLMA Maintains Buy Rating -- Price Target Lowered to $36.00 by H - GuruFocus
H.C. Wainwright lowers Olema Pharmaceuticals price target to $36 By Investing.com - Investing.com Canada
Olema Pharmaceuticals Q2 Loss Widens - marketscreener.com
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q2 Loss per Share $0.61, vs. FactSet Est of $0.55 Loss - marketscreener.com
Olema Oncology (OLMA) Advances Phase 3 Trial Enrollment Amid Mixed Market Signals - GuruFocus
Olema Pharmaceuticals falls 6% on second quarter EPS miss By Investing.com - Investing.com Canada
Olema Pharmaceuticals falls 6% on second quarter EPS miss - Investing.com
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPS - MarketBeat
Olema Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Olema Pharmaceuticals (OLMA) widens net loss but ends Q2 2026 with $461M in cash - Stock Titan
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results - Yahoo Finance
Olema Pharmaceuticals earnings up next ahead of key trial data By Investing.com - Investing.com Canada
Olema Pharmaceuticals earnings up next ahead of key trial data - Investing.com
Dimensional Fund Advisors LP Acquires 123,790 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
FMR LLC, Abigail Johnson disclose 13.8% Olema Pharmaceuticals (OLMA) ownership - Stock Titan
Olema Pharmaceuticals (OLMA) Expected to Release Quarterly Earnings on Monday - MarketBeat
Defilade Capital Management L.P. Acquires 269,902 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (OLMA) Slips 1.22% to $11.31 as Stock Tests Key Support ZoneRevenue Weighted - vinanet.vn
Janus Henderson Group PLC Boosts Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
0.69%
3.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):